Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-000471-37
    Sponsor's Protocol Code Number:CLOU064A2301
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-10-19
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-000471-37
    A.3Full title of the trial
    A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urticaria patients inadequately controlled by H1-antihistamines
    Estudio de fase III multicéntrico, aleatorizado, doble ciego, controlado con placebo para investigar la eficacia, seguridad y tolerabilidad de remibrutinib (LOU064) durante 52 semanas en pacientes adultos con urticaria crónica espontánea inadecuadamente controlados con antihistamínicos H1
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 3 study of efficacy and safety of remibrutinib in the treatment of chronic spontaneous urticaria in adults inadequately controlled by H1-antihistamines
    Estudio de fase III de eficacia y seguridad de remibrutinib en el tratamiento de la urticaria crónica espontánea en adultos
    inadecuadamente controlados con antihistamínicos H1.
    A.3.2Name or abbreviated title of the trial where available
    REMIX-1
    A.4.1Sponsor's protocol code numberCLOU064A2301
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovartis Farmacéutica S.A.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNovartis Pharma AG
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNovartis Farmacéutica S.A.
    B.5.2Functional name of contact pointTrial Monitoring Organization (TMO)
    B.5.3 Address:
    B.5.3.1Street AddressGran vía de les Corts Catalanes, 764
    B.5.3.2Town/ cityBarcelona
    B.5.3.3Post code08013
    B.5.3.4CountrySpain
    B.5.4Telephone number+3493 0353036
    B.5.5Fax number+3493 2479903
    B.5.6E-maileecc.novartis@novartis.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRemibrutinib
    D.3.2Product code LOU064
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRemibrutinib
    D.3.9.2Current sponsor codeLOU064
    D.3.9.4EV Substance CodeSUB204118
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic Spontaneous Urticaria
    Urticaria crónica espontánea
    E.1.1.1Medical condition in easily understood language
    Chronic Hives
    Urticaria crónica
    E.1.1.2Therapeutic area Diseases [C] - Skin and Connective Tissue Diseases [C17]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10072757
    E.1.2Term Chronic spontaneous urticaria
    E.1.2System Organ Class 10040785 - Skin and subcutaneous tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate that remibrutinib is superior to placebo in CSU with respect to change from baseline in UAS7 at Week 12 (Scenario 1 with UAS7 as primary efficacy endpoint) or with respect to change from baseline in ISS7 and HSS7 at Week 12 (Scenario 2 with ISS7 and HSS7 as co-primary efficacy endpoints)
    Demostrar que remibrutinib es superior a placebo en la UCE en relación con el
    cambio respecto a la basal en la puntuación semanal de la actividad de la urticaria (UAS7) (en la puntuación semanal de la intensidad del picor [ISS7] y la puntuación semanal de la intensidad de los habones
    [HSS7] para el segundo escenario de la variable principal) en la semana 12.
    E.2.2Secondary objectives of the trial
    To demonstrate:
    -that remibrutinib is superior to placebo in CSU with respect to change from baseline in UAS7 at Week 12 (only in scenario 2)
    -that a greater proportion of participants who are treated with remibrutinib compared to placebo-treated participants at Week 12:
    --achieve disease activity control (UAS7 ≤ 6)
    --achieve complete absence of hives and itch (UAS7 = 0)
    -superiority of remibrutinib treated compared to placebo-treated participants at Week 12 with respect to (only in scenario 1):
    --reduction from baseline in the ISS7
    --reduction from baseline in the HSS7
    -that a greater proportion of participants who are treated with remibrutinib compared to placebo-treated participants:
    --achieve UAS7 ≤ 6 at Week 2
    --achieve DLQI = 0-1 at Week 12
    -that remibrutinib treated compared to placebo treated participants over 12 weeks:
    --maintain disease activity control (defined as UAS7≤6) for more weeks
    --have more angioedema occurrence-free weeks
    -the safety and tolerability
    Demostrar que: remibrutinib es superior a placebo en UCE en relación con el cambio respecto a la basal en UAS7 en la sem 12 (en escenario 2); una mayor proporción de participantes tratados con remibrutinib en comparación con los participantes tratados con placebo en la semana 12: alcanzan una UAS7 ≤6 y la ausencia total de habones y picor (UAS7 = 0); superioridad en los pacientes tratados con remibrutinib en comparación con los tratados con placebo en la sem 12 (escenario 1) con respecto a: reducción respecto a la basal en ISS7 y en HSS7; una mayor proporción de participantes tratados con remibrutinib en comparación con pacientes tratados con placebo: alcanzan UAS=/<6 en la sem 2 y un DLQI = 0-1 en la sem 12; los pacientes tratados con remibrutinib en compración con los participantes tratados conplacebo en la sem 12: mantienen un control de la actividad de la enfermedad (UAS7 =/<6) durante más semanas y presentan más semanas sin angioedemas; la eficacia y la tolerabilidad
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    1) DNA sampling / Pharmacogenetics
    The study includes an optional genetic research component.
    The purpose of genetic research may be to better understand the safety and efficacy of remibrutinib, or to learn more about human diseases, or to help develop ways to detect, monitor and treat diseases.
    As technology changes over time, the most appropriate technology will be used at the time the exploratory genetic research is performed. This may include the study of the entire genome.
    The use of DNA to search for biomarkers of disease and drug action is exploratory.

    2) Additional biomarker assessments
    The study includes additional optional biomarker research components.
    Samples will be stored and analyzed depending on results of other biomarker assessments in this study, the overall study outcome, and/or other studies. Serum samples will be collected for autoantibodies assessment and the assessment of additional exploratory biomarkers.
    These serum samples may be used to better understand disease heterogeneity and for the identification of efficacy and/or stratification markers. Additionally, the effect of remibrutinib exposure on antibody titers may be assessed. The analyses may include but are not limited to IgE-autoantibodies. Detailed descriptions of the assays will be included in the bioanalytical data reports. It may also include targeted single or multiplex biomarkers panels (autoantibody, proteins, peptides or metabolites biomarkers) or hypothesis-free platforms (autoantibody, protein, peptide and metabolite biomarkers).
    The list may be changed or expanded further, as it is recognized that more relevant or novel biomarkers may be discovered during the conduct of the trial.
    3) B cell count and analysis of the B cell subsets over time for a subset of patients at selected sites:
    To explore the impact of treatment with remibrutinib on B cell count and the B cell subsets in peripheral blood
    1) Recogida de muestras de ADN/farmacogenética
    El estudio incluye un componente de investigación genética opcional.
    El propósito de la investigación genética podría ser comprender mejor la seguridad y eficacia de remibrutinib, u obtener más información acerca de las enfermedades humanas, o ayudar a desarrollar maneras de detectar, monitorizar y tratar enfermedades.
    Dado que la tecnología cambia con el tiempo, se utilizará la tecnología más apropiada en el momento en que se lleven a cabo estudios exploratorios de investigación genética. Esto puede incluir el estudio del genoma completo.
    El uso del ADN para determinar los biomarcadores de la enfermedad y la acción del fármaco es exploratorio.
    2)Evaluaciones de biomarcadores adicionales
    El estudio incluye componentes de investigación de biomarcadores adicionales. Las muestras se conservarán y se analizarán según los resultados de otras evaluaciones de biomarcadores realizadas en este estudio, el resultado global del estudio o de otros estudios. Las muestras de suero se recogerán para la evaluación de autoanticuerpos y de otros biomarcadores exploratorios. Estas muestras de suero se pueden utilizar para comprender mejor la heterogeneidad de la enfermedad y para identificar los marcadores de eficacia o estratificación. Asimismo, se puede evaluar el efecto de la exposición a remibrutinib en los títulos de anticuerpos. Los análisis pueden incluir, entre otros, autoanticuerpos IgE: Se incluirán descripciones detalladas de las pruebas en los informes de datos bioanalíticos.
    También puede incluir análisis únicos o multiplex dirigidos de biomarcadores (de autoanticuerpos, proteínas, péptidos o metabolitos) o plataformas libres de hipótesis (biomarcadores de autoanticuerpos, proteínas, péptidos y metabolitos). El listado podrá modificarse o ampliarse más, dado que podrán descubrirse biomarcadores nuevos o más relevantes durante el ensayo.
    3) El recuento de células B en sangre periférica y los subconjuntos de células B se analizarán a lo largo del tiempo en centros seleccionados.
    Investigar el efecto del tratamiento con remibrutinib en el recuento de células B y los subconjuntos de células B en el subestudio de sangre periférica
    E.3Principal inclusion criteria
    Participants eligible for inclusion in this study must meet all of the following criteria:
    - Signed informed consent must be obtained prior to participation in the study
    - Male and female adult participants ≥18 years of age
    - CSU duration for ≥ 6 months prior to screening (defined as the onset of CSU determined by the investigator based on all available supporting documentation)
    - Diagnosis of CSU inadequately controlled by second generation H1-antihistamines at the time of randomization defined as:
    --The presence of itch and hives for ≥6 consecutive weeks prior to screening despite the use of second generation H1-antihistamines during this time period
    --UAS7 score (range 0-42) ≥16, ISS7 score (range 0-21) ≥ 6 and HSS7 score (range 0-21) ≥ 6 during the 7 days prior to randomization (Day 1)
    - Documentation of hives within three months before randomization (either at screening and/or at randomization; or documented in the participants` medical history)
    - Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for the duration of the study and adhere to the study protocol
    - Participants must not have had more than one missing UPDD entry (either morning or evening) in the 7 days prior to randomization (Day 1)

    Other protocol-defined inclusion criteria may apply.
    - Se deberá obtener el consentimiento informado firmado antes de la participación en el estudio.
    - Participantes adultos de ambos sexos >/=18 años de edad.
    - Duración de la UCE >/=6 meses antes de la selección (definida como el inicio de la UCE determinado por el investigador según toda la documentación de apoyo disponible).
    - Diagnóstico de UCE inadecuadamente controlada con antihistamínicos H1 de segunda generación en el momento de la aleatorización definido como:
     -Presencia de picor y habones durante >/=6 semanas consecutivas antes de la selección a pesar del uso de
    antihistamínicos H1 de segunda generación durante este
    periodo de tiempo.
     -Puntuación de UAS7 (intervalo 0-42) >/=16, puntuación de ISS7 (intervalo 0-21) >/=6 y puntuación de HSS7 (intervalo 0-21) >/=6
    durante los 7 días anteriores a la aleatorización (día 1).
    - Documentación de habones en los tres meses previos a la aleatorización (en la selección o en la aleatorización; o
    documentados en la historia clínica de los participantes).
    - Voluntad y capacidad para cumplimentar un diario del paciente para la urticaria (DPU) durante el estudio y seguir el protocolo del estudio.
    - Los participantes no deben haber dejado sin rellenar más de una entrada en el DPU (por la mañana o por la tarde) en los 7 días anteriores a la aleatorización (día 1).
    E.4Principal exclusion criteria
    - Participants having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria
    - Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary urticaria, or drug-induced urticaria
    - Any other skin disease associated with chronic itching that might influence in the investigator’s opinion the study evaluations and results, e.g. atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis
    - Evidence of clinically significant cardiovascular (such as but not limited to myocardial infarction, unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, arrhythmia and uncontrolled hypertension within 12 months prior to Visit 1), neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant
    - Significant bleeding risk or coagulation disorders
    - History of gastrointestinal bleeding, e.g. in association with use of nonsteroidal anti-inflammatory drugs (NSAID), that was clinically relevant (e.g. requiring hospitalization or blood transfusion)
    - Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel. The use of dual anti-platelet therapy (e.g. acetylsalicylic acid + clopidogrel) is prohibited.
    - Requirement for anticoagulant medication (for example, warfarin or Novel Oral Anti-Coagulants (NOAC))
    - History or current hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or Aspartate Aminotransferase (AST)/ Alanine Aminotransferase (ALT) levels of more than 1.5 x upper limit of normal (ULN) or International Normalized Ratio (INR) of more than 1.5 at screening

    Other protocol-defined exclusion criteria may apply.
    -Participantes con un desencadenante único o predominante, claramente definido de su urticaria crónica (urticaria crónica inducible) incluida urticaria facticia (dermografismo sintomático), urticaria por frío, por calor, solar, por presión, por presión retardada, acuagénica, colinérgica o por contacto
    -Otras enfermedades con síntomas de urticaria o angioedema incluidas entre otras vasculitis urticarial, urticaria pigmentosa, eritema multiforme, mastocitosis, urticaria hereditaria o urticaria inducida por fármacos.
    -Cualquier otra enfermedad cutánea asociada a picor crónico que pueda influir según el criterio de los investigadores en las evaluaciones y los resultados del estudio; p. ej., dermatitis atópica, penfigoide bulloso, dermatitis herpetiforme, prurito senil o psoriasis.
    -Evidencia de enfermedad cardiovascular clínicamente significativa (como, entre otras, infarto de miocardio, enfermedad isquémica cardíaca inestable, insuficiencia ventricular izquierda de clase III/IV de la Asociación de Cardiología de Nueva York [NYHA], arritmia e hipertensión no controlada en los 12 meses anteriores a la visita
    1), trastornos neurológicos, psiquiátricos, pulmonares, renales, hepáticos, endocrinos, metabólicos y hematológicos, enfermedad gastrointestinal o inmunodeficiencia que, a juicio del investigador, pondría en riesgo la seguridad del participante, interferiría en la interpretación de los resultados del estudio o impediría la participación o el cumplimiento del protocolo por parte del participante.
    -Riesgo significativo de sangrado o trastornos de coagulación.
    -Antecedentes de sangrado gastrointestinal, p. ej., en asociación con el uso de fármacos antiinflamatorios no esteroideos (AINE), de interés clínico (p. ej., que requiriera hospitalización o transfusión de sangre).
    -Requisito de medicación antiplaquetaria, excepto el ácido acetilsalicílico hasta 100 mg/d o clopidogrel. El uso de tratamiento antiplaquetario dual (p. ej., ácido acetilsalicílico + clopidogrel) está prohibido.
    -Requisito de medicación anticoagulante (por ejemplo, warfarina o
    nuevos anticoagulantes orales [NACO]).
    -Antecedentes de enfermedad hepática o tratamiento actual para ello, incluida entre otras, hepatitis aguda o crónica, cirrosis o insuficiencia hepática o niveles de aspartato aminotransferasa (AST)/alanina aminotransferasa (ALT) superiores a 1,5 x el límite superior de normalidad (LSN) o índice internacional normalizado (INR) superior a 1,5 en la selección.
    E.5 End points
    E.5.1Primary end point(s)
    Absolute change from baseline in UAS7 (only in scenario 1)
    Absolute change from baseline in ISS7 (only in scenario 2)
    Absolute change from baseline in HSS7 (only in scenario 2)
    Cambio absoluto en UAS7 respecto a la basal (sólo en escenario 1).
    Cambio absoluto respecto a la basal en la puntuación ISS7 (sólo en escenario 2).
    Cambio absoluto respecto a la basal en la puntuación HSS7 (sólo en escenario 2).
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 12
    Semana 12
    E.5.2Secondary end point(s)
    - Absolute change from baseline in UAS7 (only in scenario 2)
    - Achievement of UAS7≤ 6 (yes/no) at Week 12;
    - Achievement of UAS7 = 0 (yes/no) at Week 12;
    - Improvement of severity of itch, assessed as absolute change from baseline in ISS7 score at Week 12 (only in scenario 1);
    - Improvement of severity of hives, assessed as absolute change from baseline in HSS7 score at Week 12 (only in scenario 1);
    - Achieving early onset of disease activity control, as defined as achievement of UAS7≤ 6 (yes/no) at Week 2;
    - No impact on participants' dermatology-quality of life, as defined by achievement of DLQI = 0-1 (yes/no) at Week 12;
    - Achieving sustained disease activity control, assessed as cumulative number of weeks with an UAS7≤6 response between baseline and Week 12;
    - Number of weeks without angioedema, assessed by the cumulative number of weeks with an AAS7= 0 response between baseline and Week 12;
    - Occurrence of treatment emergent adverse events and serious adverse events during the study
    -Cambio absoluto en UAS7 respecto a la basal (sólo en escenario 2).
    -Alcanzar una respuesta UAS7 </=6 (sí/no) en la semana 12.
    -Alcanzar una respuesta UAS7 = 0 (sí/no) en la semana 12.
    -La mejoría en la intensidad del picor, evaluada como cambio absoluto respecto a la basal en la puntuación ISS7 en la semana 12 (sólo en escenario 1).
    -La mejoría en la intensidad de los habones, evaluada como cambio absoluto respecto a la basal en la puntuación HSS7 en la semana 12.
    - Aparición temprana de control de la actividad de la enfermedad, definida como alcanzar
    una respuesta UAS7 </=6 (sí/no) en la semana 2
    - Ausencia de efecto en la calidad de vida en dermatología de los participantes, definida como alcanzar una respuesta DLQI = 0-1 (sí/no) en la semana 12.
    - Alcanzar un control sostenido de la actividad de la enfermedad, evaluado mediante el número acumulado de semanas con una respuesta UAS7 </=6 entre la basal y la semana 12.
    - Número de semanas sin angioedemas, evaluado mediante el número acumulado de semanas con una respuesta AAS7 = 0 entre la basal y la semana 12.
    - Aparición de acontecimientos adversos y acontecimientos adversos graves con el tratamiento durante el estudio
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 12;
    Week 2 for achieving early onset of disease activity control, defined as achievement of UAS7≤ 6 (yes/no)
    Semana 12; Aparición temprana de control de la actividad de la enfermedad, definida como alcanzar
    una respuesta UAS7 </=6 (sí/no) en la semana 2
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    Tolerabilidad
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA36
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Colombia
    India
    Japan
    Korea, Republic of
    Mexico
    Russian Federation
    Taiwan
    Turkey
    United States
    Bulgaria
    France
    Hungary
    Italy
    Portugal
    Spain
    Czechia
    Argentina
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS (last visit of the last subject)
    LPLV (última visita del último paciente)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 405
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 45
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state25
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 109
    F.4.2.2In the whole clinical trial 450
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Participants who complete 52 week treatment period of this trial may be eligible to receive remibrutinib as part of an extension study. For participants not willing or ineligible to roll over into extension study and who want to continue receiving remibrutinib every effort will be made to continue provision of study treatment prior to the IMP becoming available in the respective country, if in the opinion of the investigator, they are still deriving clinical benefit from remibrutinib.
    Pacientes que completen el pdo de tto de 52 sem de este ensayo podrían ser elegibles para recibir remibrutinib como parte de un estudio de extensión. Para participantes no dispuestos o elegibles para el estudio de extensión y que deseen continuar con remibrutinib, se hará todo lo posible para continuar proporcionándoles el tto del estudio antes del tto en investigación disponible en el país correspondiente si, en opinión del investigador, siguen obteniendo beneficio clínico de remibrutinib.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-11-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-11-10
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 04 21:05:13 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA